Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne Corporation (NASDAQ: TECH) announced preliminary data on its kidney transplant rejection test, ExoTRU™, developed with the Azzi laboratory at Harvard Medical School. This innovative, non-invasive urine-based multigene assay can distinguish between types of kidney rejection, aiding clinical decision-making and patient care. Scheduled for launch in 2021, ExoTRU demonstrates a negative predictive value (NPV) of 93.3% and a positive predictive value (PPV) of 86.2%. The test's introduction is expected to enhance monitoring and management for kidney transplant patients who face challenges with conventional methods.
Bio-Techne Corporation (NASDAQ: TECH) has agreed to acquire Asuragen, Inc. for an initial $215 million in cash, plus contingent payments of up to $105 million based on future milestones. The deal, financed through cash reserves and a credit line, is expected to close in Q4 of fiscal 2021. Asuragen, a leader in molecular diagnostics, reported over $30 million in revenue in 2020. The acquisition aims to enhance Bio-Techne's diagnostic portfolio and leverage Asuragen's expertise in molecular products, potentially driving significant growth and market expansion.
Bio-Techne Corporation (NASDAQ: TECH) announced that its CEO, Chuck Kummeth, will present at the Barclays Global Healthcare Conference on March 11, 2021, at 9:10 a.m. EST. A live webcast will be available on the company’s Investor Relations website. The company specializes in high-quality purified proteins, reagent solutions, and diagnostic products, generating $739 million in net sales in fiscal 2020. With over 2,300 employees, Bio-Techne plays a crucial role in biomedical research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) announced a new reimbursement contract with Humana, effective April 1, 2021, for the ExoDx™ Prostate (EPI) test, a genomic tool aiding in prostate biopsy decisions. Humana, the largest Medicare Advantage provider, serves about 20 million patients. The EPI test, performed by Exosome Diagnostics, is covered by Medicare and various commercial plans. This development expands access to the test, which helps reduce unnecessary invasive procedures. Bio-Techne's CEO expressed optimism about the growing acceptance of advanced diagnostics in the healthcare sector.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) announced a licensing agreement with Luminary Therapeutics for TcBuster™, its non-viral gene delivery system. This agreement allows Luminary to utilize TcBuster in their LMY-920 program, which involves advanced CAR-T therapies. The license aims to enhance the manufacturing of gene-modified cell therapies, offering benefits over viral methods. Luminary plans to file an Investigational New Drug (IND) application with the FDA later this year, marking a significant step in their therapeutic development process.
Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference on February 25, 2021, at 9:50 a.m. EST. The live webcast will be available on the company's Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and diagnostic products, generating approximately $739 million in net sales in fiscal 2020. The firm operates with over 2,300 employees globally, focusing on advancing scientific research and molecular diagnostics.
Bio-Techne Corporation (NASDAQ:TECH) announced the publication of a significant paper by Exosome Diagnostics titled Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges in the Annals of Oncology. This review highlights the advancements in exosome-based liquid biopsies, which show promise for early cancer detection. Despite progress, there's a need for improved accuracy in these tests, especially for early-stage cancers. The paper emphasizes the potential of multi-analyte measurements from exosomes as a solution to limitations in existing liquid biopsy methods.
Kantaro Biosciences, a joint venture with RenalytixAI and Bio-Techne, announced that the FDA has added its COVID-SeroKlir antibody test to the Emergency Use Authorization (EUA) for convalescent plasma treatment in hospitalized COVID-19 patients. The test, which detects SARS-CoV-2 IgG antibodies with 98.8% sensitivity and 99.6% specificity, aims to qualify high titer convalescent plasma. Kantaro emphasizes the test's potential role in advancing COVID-19 therapeutics, having been used nearly 90,000 times across diverse populations since its initial FDA authorization in November 2020.
Bio-Techne Corporation (NASDAQ: TECH) announced that Chuck Kummeth, President and CEO, will present at the 2021 SVB Leerink Global Healthcare Conference on February 24, 2021, at 11:20 a.m. EST. The live webcast can be accessed via the Investor Relations page on Bio-Techne's website. The company develops high-quality purified proteins, reagents, and diagnostic products, generating approximately $739 million in net sales in fiscal 2020. Bio-Techne's products support scientific research and clinical diagnostics, contributing significantly to drug discovery and disease understanding.